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Abstract
Background: The MRC UKALLXI trial tested the efficacy of different central nervous system (CNS) directed
therapies in childhood acute lymphoblastic leukaemia (ALL). To evaluate morbidity 555/1826 randomised children
underwent prospective psychological evaluations. Full Scale, verbal and performance IQs were measured at 5
months, 3 years and 5 years. Scores were compared in; (1) all patients (n = 555) versus related controls (n = 311),
(2) low-risk children (presenting white cell count (WCC) < 50 × 10
9/l) randomised to intrathecal methotrexate (n =
197) versus intrathecal and high-dose intravenous methotrexate (HDM) (n = 202), and (3) high-risk children (WCC ≥
50 × 10
9/l, age ≥ 2 years) randomised to HDM (n = 79) versus cranial irradiation (n = 77).
Results: There were no significant differences in IQ scores between the treatment arms in either low- or high-risk
groups. Despite similar scores at baseline, results at 3 and 5 years showed a significant reduction of between 3.6
and 7.3 points in all three IQ scores in all patient groups compared to controls (P < 0.002) with a higher
proportion of children with IQs < 80 in the patient groups (13% vs. 5% at 3 years p = 0.003).
Conclusion: Children with ALL are at risk of CNS morbidity, regardless of the mode of CNS-directed therapy.
Further work needs to identify individuals at high-risk of adverse CNS outcomes.
Trial registration: ISRCTN: ISRCTN16757172
Keywords: acute lymphoblastic leukaemia, IQ, central nervous system, morbidity, cranial radiotherapy, methotrex-
ate, neuropsychometric, paediatric
Background
Advances in the treatment of paediatric acute lympho-
blastic leukaemia (ALL) have resulted in 5 year event-
free survival rates of over 80% [1]. With such good sur-
vival, efforts are now focused on minimising treatment-
related morbidity. One area of concern is the possible
long-term effects of central nervous system (CNS) direc-
ted therapy on children.
Whilst CNS-directed treatments result in few long-
term neurocognitive impairments in adults [2], they may
adversely affect children whose neurocognitive systems
are still in the process of maturing [3]. The first reports
of adverse neuropsychological outcomes emerged in the
1970s and 80s after the introduction of universal CNS
directed therapy - usually in the form of cranial irradia-
tion (XRT) [4,5]. These initial observations led to
attempts to identify the causative agents, any additional
risk factors and the exact nature of the impairment.
There followed numerous studies examining neurocog-
nitive outcomes after various forms of CNS-directed
treatment (for recent reviews see [6,7]) but drawing
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mised by small patient numbers, differences in study
design, the vast range of tests employed, use of historical
cohorts, lack of proper control groups, non-random
assignment of different CNS-directed treatments and
changes in accompanying systemic therapy and suppor-
tive care over time [8,9].
Debate still exists over the most important causative
agents, and in particular the relative impact of different
CNS-directed treatments on neuropsychological out-
comes. Early studies using global measures of intellec-
tual functioning, such as intelligence quotients (IQs)
and academic attainment, showed fairly consistent
declines in patients treated with XRT [5,10-13]. This led
to increasing avoidance of radiotherapy in many treat-
ment protocols and, as a result, recent data are sparse.
The outcome with chemotherapy-only regimens is more
variable with some showing almost normal cognitive
functioning [14-18], and others reporting reduced IQs
[19]. A large meta-analysis [20] suggests chemotherapy
alone is associated with modest declines in IQ and other
neurocognitive functions. The relative impact of
intrathecal methotrexate (IT MTX) versus high-dose
systemic methotrexate (HDM) on CNS morbidity
remains an important unanswered question especially
since their equivalence in terms of overall survival
means that any adverse side-effects are increasingly
important.
An emerging view is that the mode of CNS-directed
therapy may have little influence on adverse outcomes
which may instead reflect the impact of the underlying
disease and/or global manifestations of treatment: Two
meta-analyses confining analysis to neuropsychological
outcomes in studies which included valid control groups
have shown that patients with ALL fare worse than con-
trols regardless of their mode of CNS-directed therapy
[20,21]. The choice of control group is vital since IQ is
highly correlated with socioeconomic status [22] making
comparison with population means inappropriate in
most small to medium scale studies. Until now a suffi-
ciently large randomised trial including an appropriate
control group has been lacking to definitively address
this question.
If the mode of treatment is not the main determinant
of adverse outcome then the search for additional risk
factors becomes even more important. A number of
small studies have identified younger age [4,10,15,23,24]
and female sex [10,25] as likely candidates. In an early
meta-analysis [5], an age of 5 years or under at initial
diagnosis was a significant factor but this study did not
examine gender differences. Girls may fare worse, parti-
cularly in some areas such as verbal IQ [26] but existing
meta-analyses are not sufficiently powered to answer
this question [20]. Moreover, age and gender factors
may interact to give rise to adverse outcome.
Against this background, the MRC UKALLXI psycho-
metric study aimed to compare prospectively the neuro-
cognitive effects of three different types of CNS-directed
therapy (HDM vs. IT MTX and HDM vs. XRT). The
s t u d yo fal a r g ec o h o r to fc h i l d r e nr a n d o m l ya l l o c a t e d
to different treatment regimens, and comparison with
an appropriate control group allowed this study to
address a number of important questions not yet reli-
ably answered in the literature i.e. 1) In modern treat-
ment protocols (with avoidance of radiotherapy in
children under 2 years of age) is the use of cranial irra-
diation still associated with adverse neuropsychometric
outcomes compared to high dose methotrexate? 2) Is
high dose systemic methotrexate associated with differ-
ent psychometric outcomes compared to intrathecal
methotrexate? 3) Does age or gender influence suscept-
ibility to adverse psychometric outcomes? 4) Can a sub-
set of children at high risk of neurological adverse
outcomes be identified to enable targeted intervention?
5) Is treatment for ALL associated with reduction in IQ
test scores in patients compared to scores in age
matched relatives?
No differences in event free survival (EFS) were seen
between the two randomised treatment arms [27], thus
increasing the importance of identifying any adverse
effects of treatment. Here, we report the results of intel-
ligence tests for patients and controls assessed at base-
line and at 3 and 5 year time-points after initiation of
treatment.
Results
During the study period 866 children had an IQ test
(555 patients; 311 controls). As shown in the accompa-
nying CONSORT diagram (Figure 1) the numbers of eli-
g i b l ep a t i e n t st e s t e da tt h et h r e et i m ep o i n t sw e r e3 0 5 /
876 (35%), 369/1137 (32%) and 289/728 (39%), respec-
tively. Thus, the proportion tested did not decrease as a
function of time from diagnosis. Psychologists were
asked to give priority to testing the high risk group, and
this is reflected in the proportion of tests done (65%
high risk, 30% low risk). Although a small proportion of
the eligible patients were not tested due to specific rea-
sons such as refusal, failure to attend for testing or prac-
tical problems (language, relocation, relapse prior to test
etc.), the vast majority of eligible but untested patients
were untested due to the time constraints of the psy-
chologist’s workload. There were no differences between
randomised arms in the proportions tested.
Further information on the tests employed, standardi-
sation of tests, statistical power calculations and choice
of controls is detailed at the end of the paper.
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There were no significant differences in Verbal (VIQ),
Performance (PIQ), or Full Scale IQ (FSIQ) scores
between patients and controls at baseline (i.e. the 5
month test). However, clear differences were seen at 3
and 5 years in all three IQ scores (Table 1).
To explore this observed difference in IQ between
patients and controls further, we examined the
CONSORT diagram 
 
 
 
       
  
 
 
 
 
 
  
 
 
 
 
5 month test 
 
 
 
  
 
 
  
 
  
 
3 year test 
 
 
  
 
 
 
 
  
 
 
5 year test 
 
 
  
 
 
 
 
 
   
2101 entered 
11 misdiagnosis 
264 not randomised 
30 Down Syndrome 
8 no CR 
129 entered from Ireland 
1659 eligible for psychometric study 
15 relapsed, died, received BMT or lost before due date 
35 aged <2 years at 5 months 
733 test due outside testing period 
571 no test result (47 refused, 13 failed to attend 
test, 21 practical problems, 4 tests not completed, 
5 relapsed before test, 481 reason unknown) 
305 tested 
414 relapsed, died, received BMT or lost 
25 aged over 17 years 
83 test due outside testing period 
1137 eligible for test 
768 no test result (58 refused, 35 failed to attend 
test, 21 practical problems,16 tests not 
completed, 57 relapsed before test, 581 reason 
unknown) 
369 tested 
585 relapsed, died, received BMT or lost 
56 aged over 17 years 
290 test due outside testing period 
439 no test result (67 refused, 25 failed to 
attend test, 27 practical problems, 5 tests 
not completed, 6 relapsed before test, 309 
reason unknown)  289 tested 
2090 eligible for trial 
728 eligible for test 
876 eligible for test 
Figure 1 CONSORT Diagram.
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since an IQ at this level would be expected to be func-
tionally significant. At 5 months (baseline) there was no
statistically significant difference in the proportion of
patients with IQ scores (FSIQ, VIQ or PIQ) below 80.
At 3 years 13% of patients and 5% of controls had FSIQ
scores less than 80 (p = 0.003), with smaller but still sig-
nificant differences in the proportions with FSIQ < 80 at
5 years (11% vs. 5% p = 0.03).
Treatment Comparisons: Low Risk Group (HDM/IT MTX
versus IT MTX)
The mean differences in FSIQ, PIQ or VIQ between
patients randomised to HDM and IT MTX and those
randomised to IT MTX alone were small, and non-sig-
nificant, at 3 years and at 5 years (table 2), with confi-
dence intervals ruling out 6 point differences. These
results remain unchanged after allowing for age at the
start of treatment, gender and number of previous tests
taken. In addition, examining the proportion of patients
with an IQ < 80 showed no differences by treatment
allocation (data not shown).
Treatment Comparisons: High Risk Group (HDM/IT MTX
versus short course IT MTX/XRT)
As shown in table 3 there were no significant differences
in FSIQ, PIQ or VIQ between patients randomised to
high dose methotrexate and those randomised to cranial
irradiation at 3 years or at 5 years, but the mean differ-
ences were somewhat larger in this group, and confi-
d e n c ei n t e r v a l sa r ew i d e( d u et ot h es m a l l e rn u m b e r s
tested) and can only rule out differences of 10 points.
These results were unchanged when allowing for age at
the start of treatment, gender, and the number of pre-
vious tests taken. Again, analysis of the proportion of
patients with a FSIQ < 80 showed no difference by
treatment allocation (data not shown).
Effects of age and gender
As shown in Table 4 there was no evidence of differen-
tial effects on mean IQ scores between those aged
under 5 years at the start of treatment and those aged 5
years and above. This was true for all 3 comparison
groups - controls versus patients, IT MTX vs. HDM
a n dH D Mv s .X R T .U s i n gt h em e a s u r eo fI Q<8 0 ,w e
Table 1 IQ scores of patients and controls at each time period
Number tested Mean adjusted IQ* (SD) Difference in
means
(95% CI)
t-test
p-value
Controls Patients Controls Patients
FSIQ
5 months 157 284 102.5
(14)
101.0
(15)
1.4
(-1.5 : 4.4)
0.3
3 years 173 366 104.8
(14)
97.7
(16)
7.1
(4.4 : 9.8)
< 0.0001
5 years 132 289 105.2
(15)
100.0
(16)
5.2
(1.9 : 8.5)
0.002
VIQ
5 months 158 287 102.0
(14)
99.6
(15)
2.3
(-0.5 : 5.2)
0.1
3 years 173 366 103.4
(15)
97.7
(15)
5.7
(3.1 : 8.4)
< 0.0001
5 years 132 289 103.2
(14)
99.6
(15)
3.6
(0.5 : 6.7)
0.02
PIQ
5 months 160 299 102.5
(15)
102.0
(16)
0.5
(-2.5 : 3.5)
0.7
3 years 173 368 105.5
(15)
98.2
(16)
7.3
(4.5 : 10.1)
< 0.0001
5 years 132 289 106.4
(16)
100.5
(17)
5.9
(2.5 : 9.3)
0.0006
*IQ adjusted for test by subtracting:
7.15 from each WPPSI-R full IQ
3.79 from each WPPSI-R verbal IQ.
8.74 from each WPPSI-R performance IQ.
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low-functioning individuals. By this criterion those aged
< 5 years at the start of treatment were more likely to
have a FSIQ < 80 at their 3 year test point than those
aged > 5 years (17% vs. 7% respectively, P = 0.005).
The effect of gender on IQ was examined by multiple
regression analysis. No statistically significant differences
were seen between mean IQ scores in male and female
patients in any of the groups.
There was no effect of gender on the proportion of
patients with an IQ < 80 (data not shown).
Discussion
We present here the largest study of neuropsychological
outcomes in children treated for ALL. In addition to
Table 2 IQ in low risk randomisation groups (HDM versus
intrathecal MTX)
Number of
patients
Mean
adjusted IQ*
(SD)
Difference in
means
(95% CI)
t-test
p-value
HDM IT MTX HDM IT MTX
FSIQ
3 years 138 132 97.9
(16)
98.3
(16)
-0.4
(-4.4 : 3.5)
0.8
5 years 116 104 99.5
(15)
100.9
(18)
-1.4
(-5.8 : 3.0)
0.5
VIQ
3 years 138 132 97.8
(15)
98.2
(15)
-0.4
(-4.0 : 3.3)
0.8
5 years 116 104 99.2
(14)
100.3
(17)
-1.1
(-5.2 : 3.0)
0.6
PIQ
3 years 138 132 98.1
(17)
99.0
(17)
-1.0
(-5.0 : 3.1)
0.6
5 years 116 104 100.2
(15)
101.3
(19)
-1.1
(-5.7 : 3.4)
0.6
*IQ adjusted for test by subtracting:
7.15 from each WPPSI-R full IQ.
3.79 from each WPPSI-R verbal IQ.
8.74 from each WPPSI-R performance IQ.
Table 3 IQ in high risk randomisation groups (HDM
versus XRT)
Number of
patients
Mean
adjusted IQ*
(SD)
Difference in
means
(95% CI)
t-test
p-value
HDM XRT HDM XRT
FSIQ
3 years 45 51 98.9
(13)
94.7
(13)
4.2
(-1.1 : 9.4)
0.1
5 years 35 34 100.5
(16)
98.2
(15)
2.3
(-5.1 : 9.8)
0.5
VIQ
3 years 45 51 98.9
(14)
94.9
(13)
4.0
(-1.5 : 9.5)
0.2
5 years 35 34 100.3
(16)
98.2
(15)
2.0
(-5.5 : 9.6)
0.6
PIQ
3 years 45 51 99.4
(13)
95.7
(13)
3.7
(-1.5 : 8.8)
0.2
5 years 35 34 101.0
(15)
98.4
(14)
2.7
(-4.3 : 9.7)
0.4
* IQ adjusted for test by subtracting
7.15 from each WPPSI-R full IQ.
3.79 from each WPPSI-R verbal IQ.
8.74 from each WPPSI-R performance IQ.
Table 4 Effect of age and gender on mean difference in FSIQ
Difference in mean FSIQ
(95% CI)
p-value Difference in mean FSIQ
(95% CI)
p-value
Age < 5 Age > 5 Male Female
Controls vs. patients
3 years 7.7
(3.7: 11.7)
5.0
(1.2: 8.8)
ns 8.3
(4.5: 12.1)
5.6
(1.7: 9.5)
ns
5 years 5.6
(1.3: 9.9)
3.6
(-1.5: 8.7)
ns 5.5
(1.1: 9.9)
4.6
(-0.4: 9.6)
ns
HDM vs. IT MTX
3 years -0.1
(-4.9: 4.6)
1.0
(-5.7: 7.7)
ns -0.9
(-6.4: 4.5)
0.0
(-5.7: 5.8)
ns
5 years 1.6
(-3.5: 6.7)
-6.6
(-14.5: 1.3)
ns -1.3
(-7.6: 5.0)
-1.7
(-8.0: 4.6)
ns
HDM vs. XRT
3 years 4.2
(-3.4: 11.9)
4.2
(-3.5: 11.8)
ns 3.6
(-3.8: 11.0)
4.8
(-3.1: 12.6)
ns
5 years 5.5
(-5.9: 13.4)
-0.4
(-10.8: 10.0)
ns 2.1
(-7.0: 11.2)
1.5
(-12.2: 15.2)
ns
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mized with respect to treatment regimes, a prospective
design, and the inclusion of a control group of healthy
children. Despite the recognised problems of using dif-
ferent tests and standardizations for different age groups
this study has produced clear results.
Firstly, there were no significant differences between
patients randomised to continuing intrathecal metho-
trexate alone compared with those randomised to addi-
tional high dose methotrexate. This was true for both
the under, and the over 5-year old age groups, and for
both sexes. The numbers of participants in these com-
parisons were large allowing reasonable confidence that
important differences do not exist. These findings are
consistent with the majority of smaller studies [14-18]
and meta-analyses [20] in the literature.
Similarly, we found no significant differences in IQ
scores in those randomised to cranial irradiation com-
pared with those randomised to high dose methotrexate.
Although possibly unexpected, our results mirror those
of another recent study showing that with modern pro-
tocols the neuropsychological outcomes for XRT and
chemotherapy-only groups are very similar [28]. Impor-
tantly, the UKALL XI protocols used a relatively high
dose of cranial irradiation (24 Gy) further strengthening
results of Waber [28] whose protocols only used 18 Gy.
In addition, relatively early folinic acid rescue (commen-
cing 36 hours after the start of the HDM infusion) may
have reduced late effects of HDM. Both of these factors
would have been expected to widen any gap between
HDM and XRT in terms of adverse effects. These
results contrast with earlier reports of significant
impacts of cranial irradiation on IQ and other measures
of intellectual functioning [4,13,14,18,24,29]. Several
possibilities may explain these discrepant results. Firstly,
the majority of studies showing adverse effects of cranial
radiotherapy included very young children, and in many
the adverse effects of radiotherapy were strongly asso-
ciated with the younger age groups
[10,14,18,24,25,29,30]. Since radiotherapy is thought to
cause neurotoxicity predominantly by demyelination
[31] and myelination is not complete until much later in
childhood, younger children would be expected to be
particularly vulnerable. Our study avoided all radiother-
apy in children under 2 years of age and in addition the
XRT randomisation was confined to children with a
WCC > 50 - a biological feature associated with older
age. Secondly, the use of an adequate control group is
vital since studies that showed a detrimental effect of
radiotherapy may have been demonstrating a detrimen-
tal effect of ALL and its treatment rather than a specific
effect of XRT alone [5]. This is supported by carefully
controlled longitudinal studies from the St Jude group
which showed no difference between XRT and
chemotherapy groups at a single time point [32], but
subsequent longitudinal follow-up showed a decline in
both treatment groups over time [26,33]. Thirdly, most
reports of XRT effects pre-date the current treatment
era and therefore changes in accompanying systemic
therapy, supportive care or improved delivery methods
may have either reduced the morbidity from cranial
radiotherapy or narrowed the gap by increased neuro-
toxicity with intensified systemic therapy. This is sup-
ported by data from animal models [34] and patients
[35] suggesting that systemic chemotherapy can have
synergistic or protective effects when combined with
XRT. Finally, the majority of previous reports involved
non-randomised, retrospective studies of small numbers
of patients and may have therefore been inadvertently
biased towards recruitment of children with poorer out-
comes and/or publication bias.
Although overall our data do not suggest that age is a
significant risk factor for mean IQ values, children aged
less than 5 years at initial diagnosis are more likely to
have IQ below 80 at 3 years compared to children aged
over 5 years at diagnosis, irrespective of treatment allo-
cation. This is consistent with models of brain develop-
ment suggesting that younger children are likely to be
particularly vulnerable to neurotoxic insults. These data
also highlight that mean IQ values may mask significant
individual declines in IQ as discussed below.
The finding of similar outcomes in males and females
is reassuring. Initial reports of inferior outcomes in girls
came from relatively small studies using combinations
of methotrexate and cranial radiotherapy [10,25]. More
recently a number of chemotherapy-only protocols have
also shown inferior outcomes in girls [17], although a
meta-analysis of chemotherapy-only protocols could not
reach a firm conclusion [20]. The possible underlying
mechanisms for gender differences in neuropsychologi-
cal outcome in ALL are poorly understood and in fact
in other areas of acute brain injury, such as head injury,
girls usually have better outcomes than boys. Again,
changes in therapy protocols such as lack of co-adminis-
tration of high-dose methotrexate and avoidance of
radiotherapy in young patients may explain the lack of
difference in IQ in our studies.
Importantly, despite the lack of effect of randomised
treatment allocation on IQ, patients definitely fared
worse than controls, with a lower mean IQ of between 5
and 7 points. The effect was seen for FSIQ, VIQ and
PIQ. A reduction in IQ score of this magnitude may be
of only modest impact in children with average or above
average initial IQ scores but importantly this effect also
translates into a larger proportion of children with IQ
scores less than 80 - a level consistent with low intellec-
tual functioning. These results suggest that children
treated for ALL are at risk of neurodevelopmental
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directed therapies they received. This has previously
been suggested by smaller studies [33,36], a meta-analy-
sis [21], and a recent larger study [28] which reported
some selective weaknesses in verbal IQ and mathematics
fluency in all children with ALL regardless of their treat-
ment allocation. It is also supported by a lack of dose
response for both radiotherapy [26] (18 Gy vs. 24 Gy)
and methotrexate [18] (HDM vs. very high dose MTX).
It is known that even intrathecal methotrexate alone
can be associated with white matter changes, calcifica-
tions, leukoencephalopathy, cortical atrophy, and sei-
zures in some patients [37].
Some important limitations of our study should be
acknowledged. A cross-sectional design was necessary to
maximise patient recruitment in order to answer the
main study questions but this design makes it impossi-
ble to track the unfolding of impairments in individual
patients over time. The large numbers of participants,
balanced randomisation and inclusion of a socioecono-
mically matched control group makes substantial demo-
graphic differences in the tested cohorts in the different
arms at 3 time-points unlikely, but some alteration in
the demography of the groups over time cannot be
excluded, and it is possible that this may explain
improvement in scores at 5 years. Secondly, IQ tests are
a relatively global measure of intelligence. A multitude
of more specific defects have been reported in the litera-
ture with a particular propensity for domains such as
attention, arithmetic fluency, non-verbal reasoning, to
be affected [13,15,38]. We chose to investigate IQ as a
primary outcome measure because it was so well stan-
dardised and relatively robust but these results do not
exclude the possibility of specific influences of our ran-
domised treatment arms on more subtle but important
neuropsychological measures. Whilst investigation of
these additional measures would obviously add to our
findings it does not detract from our major observation
of a difference in mean IQ between patients and
controls.
Overall these data suggest that factors other than the
mode of CNS directed treatment determine the likeli-
hood of CNS morbidity and that there may be vulner-
able groups of children who manifest large declines in
IQ whilst others are relatively unaffected. That mean IQ
scores comfortably fall in the average range will be a
huge reassurance to most parents and patients - atten-
tion now needs to be focussed on identifying the smaller
subset of vulnerable children. Study of these children
(alongside matched unaffected controls) should allow
identification of possible risk-factors. Candidates
include; inherent genetic susceptibility, drug toxicity,
time out of full-time education or particular vulnerabil-
ity of certain individuals to the impact of chronic illness.
Pharmacogenomic and genome wide association studies
comparing severely affected children with those with
persistently normal IQs should help identify genetic and
drug-related risk factors. Indeed a recent report impli-
cates polymorphisms in folate metabolism pathways as a
risk factor for CNS morbidity [39]. Correlative neuro-
imaging may also help identify aetiology, as it is possible
to quantify leukoencephalopathy using MRI [40] and
functional MRI offers an exciting new approach [41].
Systemic drugs used in all children with ALL include
anti-folates, steroids and nucleoside analogues all of
which have documented neurotoxic side effects
[30,42,43]. The equivalent results in pre-school and
older children argue against frequent and/or prolonged
absence from school being the primary cause for the
observed reduction in IQ.
Conclusions
In summary, with modern protocols and avoidance of
XRT for very young children, the neuropsychological
outcomes for XRT and chemotherapy-only groups are
very similar. We are unable to confirm female gender as
a risk factor, but children aged below 5 years may be
more vulnerable to treatment related neurotoxic effects.
The most striking finding of this study is the difference
observed between patients and controls, regardless of
the CNS treatment delivered. This supports the view
that ALL itself, and the necessity for intensive treatment,
has a detrimental effect on IQ in some children.
Detailed longitudinal neuropsychological assessments
should allow individualised risk factors for neurocogni-
tive morbidity to be examined. We predict that
improvements in neuropsychological outcomes for chil-
dren with ALL will depend more on individualised ther-
apy for children at high risk of CNS morbidity than on
avoidance of specific CNS-directed therapy regimens in
unselected patient cohorts.
Patients and Methods
The UKALLXI Trial
Between 1990 and 1997 a total of 2090 patients with
ALL entered UKALLXI, with 1826 randomized for
CNS-directed therapy. Low-risk children (presenting
WBC < 50 × 10
9/ l )( n=1 5 1 3 )w e r er a n d o m i z e d
between intrathecal methotrexate alone (IT MTX) or in
combination with high dose intravenous methotrexate
(HDM) (8 g/m
2 for those below 4 years of age and 6 g/
m
2 for those aged 4 years or above, folinic acid rescue
commenced at 24 hours). High-risk children (presenting
WBC of ≥ 50 × 10
9/l) (n = 313) were randomized to
receive HDM and continuing IT MTX or a short course
of IT MTX followed by cranial irradiation (XRT) (2400
Gy), with the exception of those under the age of 2
years who were all allocated HDM. The 26 children
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therapy and excluded from this study. For details of the
full treatment regimen see Table 5. There were no sig-
nificant differences in event-free survival by treatment
allocation [27].
The UKALL XI Neuropsychological Study
All UKALLXI randomised patients aged between 2 and
16 years were eligible for the Neuropsychological study
except children with Down syndrome, or those who had
relapsed or undergone bone marrow transplantation.
Where possible, one healthy related control was
recruited for each index patient. Relatives were chosen
as controls to ensure reasonable matching for socioeco-
nomic status and disruption to normal family life and
because IQ is generally well correlated between siblings
[44]. Where more than one potential control was avail-
able they were selected by closest age, followed by gen-
der. If no sibling control was available, cousins (of
similar age and/or gender) were invited to participate.
L a c ko fas u i t a b l ec o n t r o ld i dn o te x c l u d eap a t i e n t
from the study.
Table 5 UKALL XI treatment regimen
Induction Vincristine 1·5 mg/m
2 i.v. days 1, 7, 14, 21
Weeks 1-4 Prednisolone 40 mg/m
2 p.o. days 1-28
L-Asparaginase 6000 U/m
2 s.c./i.m. t.i.w. nine doses
IT MTX days 1, 8
Intensification Vincristine 1·5 mg/m
2 i.v. day 1
Weeks 5-7 Prednisolone 40 mg/m
2 p.o. days 1-7 then 7 d taper
Etoposide 100 mg/m
2 i.v. days 1-5
Cytarabine 100 mg/m
2 i.v. given 12 hourly days 1-5
Daunorubicin 45 mg/m
2 days 1, 2
Thioguanine 80 mg/m
2 p.o. days 1-5
IT MTX day 1
Intensification Vincristine 1·5 mg/m
2 i.v. day 1
Weeks 20-22 Prednisolone 40 mg/m
2 p.o. days 1-5
Etoposide 100 mg/m
2 i.v. days 1-5
Cytarabine 100 mg/m
2 i.v. given 12 hourly days 1-5
Daunorubicin 45 mg/m
2 days 1, 2
Thioguanine 80 mg/m
2 p.o. days 1-5
IT MTX day 1
CNS-directed treatment weeks 8-19:
Randomization WBC ≤ 50 × 10
9/l
IT MTX weekly (weeks 9-12) or HDM 6 g/m
2 (≥ 4 years old) or 8 g/m
2 (< 4 years old) weeks 9, 11,
13 + IT MTX weeks 9, 11, 13, 14. HDM
IV over 24 hours, folinic acid rescue commenced at 36 hours from start at 15 g/m
2 3-hourly,
reduced to 15 g/m
2 6-hourly once serum MTX level < 2 × 10
6 mol/l and stopped once serum MTX
level below 1 × 10
7 mol/l.
CNS-directed treatment weeks 8-19:
Randomization WBC ≥ 50 × 10
9/l
HDM + IT MTX as above or 24 Gy cranial radiotherapy in 15 fractions of 1·6 Gy each in weeks 9-12
(except children of 1-2 years age who were allocated HDM)
Plus IT MTX weeks 9-11
Interim continuation therapy Mercaptopurine 75 mg/m
2 p.o. daily
Weeks 8-19 Methotrexate 20 mg/m
2 p.o. weekly except when ITMTX given
and 23-34 Vincristine 1·5 mg/m
2 i.v. every 4 weeks
Prednisolone 40 mg/m
2 p.o. daily × 5 d every 4 weeks.
Continuation therapy Weeks Same as above ± 3-monthly ITMTX
35 or 43-100 Age-adjusted
Third intensification Weeks 35-42 Dexamethasone 10 mg/m
2 p.o. for 10 d then 4 d taper
Vincristine 1·5 mg/m
2 i.v. days 1, 7, 14, 21
L-Asparaginase 6000 U/m
2 s.c./i.m. t.i.w. nine doses
IT MTX (age-adjusted) days 1, 28
Cyclophosphamide 600 mg/m
2 i.v. days 28, 42
Cytarabine 75 mg/m
2 i.v./s.c. days 28-31, 35-38, 42-45, 49-52
Thioguanine 60 mg/m
2 p.o. days 28-56
1. IT MTX, intrathecal methotrexate; HDM, high-dose intravenous methotrexate; t.i.w, given on alternate days for three days each week.
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months, 3 years and 5 years from the start of treatment
for patients, and at comparable intervals for their con-
trols. Some flexibility was allowed around the ideal test
date: Within the first year for the 5 month test, and 1
year either side of both the 3- and 5-year test dates. The
study was not designed as a longitudinal study, but
rather as a cross-sectional prospective study, in order to
maximise the number of follow-up tests completed (at 3
and 5 years) by patients within the period of funding.
Thus the neuropsychological study did not commence
until 2 years into the UKALL XI trial and preference
was always given to 3 and 5 year tests over 5 month
tests if a choice had to be made.
Table 6 summarises the numbers of children tested in
each category and time point. There were no significant
differences in age, time of testing, or gender by rando-
mised treatment allocation. Controls were older, with a
median age of 6 years for controls and 4 years for
patients (p < 0.001) and tested at a median of 1-2
months later (p < 0.005) than patients.
Neuropsychological assessment
Three standardized scales were used to evaluate intellec-
tual ability (IQ): Children aged ≥ 2 to < 6 years were
assessed on the Wechsler Preschool and Primary Scale
of Intelligence - Revised (WPPSI-R); children aged ≥ 6
to < 17 years on the Wechsler Intelligence Scale for
Children - 3
rd Edition UK (WISC-III); and those aged ≥
17 years and above on the Wechsler Adult Intelligence -
Revised Scale (WAIS-R). Scaled subtest scores were
summed to obtain estimates of Full Scale IQ (FSIQ),
Verbal IQ (VIQ), and Performance IQ (PIQ). All IQ
scores are standardized (mean = 100, standard deviation
= 15).
T h em a j o r i t yo fc h i l d r e ni nitially assessed on the
WPPSI-R scale moved on to the WISC-III scale at their
3 year or 5 year test points (as they entered the 6-16
age range). Changes in the assessment tool can produce
an apparent drop in IQ over time [8,26,45,46], and
therefore it was important to carefully consider their
equivalence. Analysis of results from the first test taken
by controls (n = 311) showed that WPPSI-R scores were
higher than WISC-III scores for FSIQ (difference 7.15: p
< 0.0001), VIQ (difference 3.79: p = 0.04), and PIQ (dif-
ference 8.74: p < 0.0001) (Table 7). Due to these large
differences, all WPPSI-R test scores were adjusted
downwards by subtraction of 7.15, 3.79 and 8.74 from
FSIQ, VIQ and PIQ scores respectively. These adjusted
IQ scores were used for subsequent analysis. Where
possible, results were validated by allowing for “type of
test” (WISC-III, WPPSI-R or WAIS-R) as a covariate in
a multiple regression model.
Practice effects over time
Although IQ scores in an individual are generally stable
over time, there are reported increases of 7-8 points in
FSIQ score if the re-test interval is short. An interval of
6-12 months is reportedly sufficient to nullify these so
called practice effects [47]. Practice effects are different
f o rV I Qa n dP I Q ;v e r yl o wi nt h ec a s eo ft h ef o r m e r ,
but much higher in the case of the latter.
Analysis of the IQ scores in our control group sug-
gests the presence of a practice effect. Out of 132 con-
trols tested at the 5 year time point, 37 were taking
their first test, 65 their second and 30 their third. The
corresponding FSIQ means were 101, 106 and 109
respectively. A one-way analysis of variance exploring
the 5 year FSIQ by the number of previous tests taken
yielded a p-value of p = 0.02. For the 3-year tests, con-
trols taking their second test had a mean FSIQ of 107
(n = 60), compared to a mean of 103 (n = 113) in those
Table 6 Numbers assessed at each time period in each
treatment group
Control Patient
Any High Risk Low Risk
XRT HDM HDM IT
MTX
Any test 311 555 77 79 202 197
5 month test 161 305 47 42 104 112
3 year test 173 369 51 45 139 134
5 year test 132 289 34 35 116 104
5 month only 92 133 23 28 35 47
3 year only 57 94 15 16 34 29
5 year only 37 40 3 6 21 10
5 month and 3 year
only
30 39 5 0 17 17
5 month and 5 year
only
9 1 3 0 076
3 year and 5 year only 56 116 12 15 43 46
All 3 tests 30 120 19 14 45 42
Table 7 First IQ score by test type: Controls only
First test WPPSI-R v WISC-III
WAIS-R
(n = 9)
WPPSI-R
(n = 87)
WISC-III
(n = 215)
Difference
in IQ
t-test
p-value
FSIQ (mean)
(std dev)
104.00
(13.6)
n=9
109.75
(14.0)
n=8 4
102.60
(13.6)
n = 214
7.15 < 0.0001
VIQ (mean)
(std dev)
100.33
(14.7)
n=9
106.08
(13.6)
n=8 4
102.30
(14.0)
n = 215
3.79 0.04
PIQ (mean)
(std dev)
108.33
(13.4)
n=9
111.17
(14.6)
n=8 7
102.43
(14.3)
n = 214
8.74 < 0.0001
Halsey et al. Journal of Hematology & Oncology 2011, 4:42
http://www.jhoonline.org/content/4/1/42
Page 9 of 12previously untested (p = 0.08). As a result of these find-
ings, the number of previous tests performed was
included as a covariate in multiple regression models.
Finally, IQ test scores have increased over the years
(the Flynn effect) [48]. Examination of the controls’ data
sets failed to show any time-related changes. Since the
study duration was short, this effect was not considered
further.
Statistics
Since intelligence scores are normally distributed, t-tests
were employed for these analyses, and multiple regres-
sion methods (using the SAS procedure GLM) were
used to validate these results, with the p-value for het-
erogeneity taken from the relevant interaction term. The
Mann Whitney U-test (2 groups) and Wilcoxon’sR a n k
Sum Test (multiple groups) were used for comparisons
of non-normal scores. Gender by treatment group was
investigated using the chi-square test - and Fisher’s
exact test when the expected numbers were small. All
analyses were performed using the SAS statistical
package.
T h em a i na i mw a st oc o m p a r et h eI Qs c o r e so ft h e
randomised treatment groups at follow-up. Power calcu-
lations were based on estimated effect sizes from the
largest meta-analysis available at the time [5]. The target
number in the high-risk group was 112 patients tested
at 3 years, to give 90% power to detect a difference of 9
points in the full IQ scores. The target number in the
low-risk group was 438 patients tested at 3 years, giving
over 95% power to detect a difference of 4 points in the
full IQ score. Further power calculations were per-
formed to estimate required sample numbers for sub-
group analysis of the effect of age on IQ with 56
patients in each group required to give an 80% chance
of detecting a difference of 10 IQ points in the high risk
group, and 219 patients in each group required to give
an 85% chance of detecting a difference of 4 IQ points
in the low risk group.
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